Summary
Eli Lilly & Company (LLY) announced a significant addition to its Board of Directors, electing Dr. Carolyn R. Bertozzi, a distinguished professor from Stanford University and Howard Hughes Medical Institute investigator, effective December 8, 2025. Dr. Bertozzi brings a wealth of expertise in Chemistry, Chemical & Systems Biology, and Radiology, positions that will be highly relevant to Lilly's ongoing innovation and development in the pharmaceutical sector. Her appointment is intended to bolster the Board's strategic direction, particularly through her service on the Science and Technology Committee and the Ethics and Compliance Committee. Dr. Bertozzi's independence has been confirmed, and she will participate in the company's standard director compensation. This move signals Lilly's commitment to leveraging cutting-edge scientific knowledge at the highest governance level.
Key Highlights
- 1Eli Lilly & Company (LLY) has elected Dr. Carolyn R. Bertozzi as a new member of its Board of Directors, effective December 8, 2025.
- 2Dr. Bertozzi is a highly respected academic, holding professorships at Stanford University and serving as an investigator at the Howard Hughes Medical Institute.
- 3Her expertise spans Chemistry, Chemical & Systems Biology, and Radiology, aligning with Lilly's scientific endeavors.
- 4Dr. Bertozzi will contribute to the Board's strategic oversight by serving on the Science and Technology Committee and the Ethics and Compliance Committee.
- 5The company has affirmed Dr. Bertozzi's independence according to NYSE and company guidelines.
- 6Dr. Bertozzi will be subject to the company's standard director compensation plan.
- 7She is not involved in any undisclosed transactions with the company.